Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nektar Starts Major Push In Opioid-Induced Constipation Space

Executive Summary

Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters

You may also be interested in...

Nektar Dips Into AstraZeneca's Deep Pockets With OIC Deal

As Nektar reinvents itself, the specialty drug developer gets multi-million dollar validation from AstraZeneca in deal for NKTR-118.

Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals

"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth

Niche, Lackluster: Two Words That Sum Up 2008 NME Launches

The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts